pipette
ENEnglish

Cell surface proteomics of patient-derived malignant rhabdoid tumor organoids identifies ROBO1 as CAR T cell target for pediatric solid tumors

Juliane L. Buhl, Jannet Koelewijn, Charlotte op ’t Hoog, Li Yang, Stijn De Munter, Victoria M. Cruz, D Chin, Baojie Zhang, Marliek van Hoesel, Nienke van Herk, Mariëtte E.G. Kranendonk, Mariel O. Brok, Irene Paassen, Katie Nachataya, Laura Hofman, Ella de Boed, Stefan Nierkens, Patrick Kemmeren, Annelisa M. Cornel, Wei Wu, Bart Vandekerckhove, Jarno Drost, Claudia Y. Janda

Revista con revisión por paresAfirmaciones fuertes, leer con cuidadoUso en el mundo real

En palabras de los autores

Abstract Malignant rhabdoid tumors are highly aggressive pediatric malignancies with limited treatment options and poor outcomes. To expand therapeutic options, we employed mass spectrometry-based cell surface proteomics on malignant rhabdoid tumor and patient-matched normal kidney organoids to identify potential CAR T cell targets. Integrating these findings with transcriptomics and protein expression data, we revealed ROBO1 as a promising target, showing strong and uniform expression across malignant rhabdoid and other pediatric tumors. ROBO1-targeted CAR T cells displayed potent anti-tumor activity in vitro , effectively eliminating tumor cells in co-cultures with organoids from malignant rhabdoid tumors, rhabdomyosarcoma, and neuroblastoma. In vivo, ROBO1 CAR T cells infiltrated tumors, induced potent tumor regression and significantly increased survival in malignant rhabdoid tumor-bearing mice. These findings establish ROBO1 as a compelling therapeutic target for CAR T cell therapy and offer a promising approach to address the critical need for effective treatments in high-risk pediatric solid tumors. Statement of significance This study identifies ROBO1 as a promising CAR T cell target for pediatric solid tumors. Using patient-derived tumor organoids and tissues, we demonstrate strong ROBO1 expression across several tumor entities and robust anti-tumor efficacy of ROBO1-targeted CAR T cells in vitro and in vivo , underscoring its potential for clinical translation.

Resultado principalEl resumen no menciona limitaciones.

Apareció: lunes, 2 de noviembre. Nature Communications. Revista con revisión por pares.

DOI: 10.1038/s41467-026-79142-z